CRISPR Therapeutics (NASDAQ:CRSP) Given New $120.00 Price Target at Truist Financial
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by equities researchers at Truist Financial from $100.00 to $120.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Truist Financial’s price target points to a potential upside of 175.93% from the stock’s previous close. […]
CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) had its price target hoisted by equities researchers at Truist Financial from $100.00 to $120.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Truist Financial’s price target points to a potential upside of 175.93% from the stock’s previous close. […]
